3,3',5-Triiodothyroacetic Acid Transporters.

IF 5.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Thyroid Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI:10.1089/thy.2023.0467
Zhongli Chen, Sena Yildiz, Boyka Markova, Linda J de Rooij, Selmar Leeuwenburgh, Timo Hamers, Robin P Peeters, Heike Heuer, Marcel E Meima, W Edward Visser
{"title":"3,3',5-Triiodothyroacetic Acid Transporters.","authors":"Zhongli Chen, Sena Yildiz, Boyka Markova, Linda J de Rooij, Selmar Leeuwenburgh, Timo Hamers, Robin P Peeters, Heike Heuer, Marcel E Meima, W Edward Visser","doi":"10.1089/thy.2023.0467","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Thyroid hormone transporters are essential for thyroid hormones to enter target cells. Monocarboxylate transporter (MCT) 8 is a key transporter and is expressed at the blood-brain barrier (BBB), in neural cells and many other tissues. Patients with MCT8 deficiency have severe neurodevelopmental delays because of cerebral hypothyroidism and chronic sequelae of peripheral thyrotoxicosis. The T3 analog 3,3',5-triiodothyroacetic acid (TRIAC) rescued neurodevelopmental features in animal models mimicking MCT8 deficiency and improved key metabolic features in patients with MCT8 deficiency. However, the identity of the transporter(s) that facilitate TRIAC transport are unknown. Here, we screened candidate transporters that are expressed at the human BBB and/or brain-cerebrospinal fluid barrier and known thyroid hormone transporters for TRIAC transport. <b><i>Materials and Methods:</i></b> Plasma membrane expression was determined by cell surface biotinylation assays. Intracellular accumulation of 1 nM TRIAC was assessed in COS-1 cells expressing candidate transporters in Dulbecco's phosphate-buffered saline (DPBS)/0.1% glucose or Dulbecco's modified Eagle's medium (DMEM) with or without 0.1% bovine serum albumin (BSA). Expression of Slc22a8 was determined by fluorescent <i>in situ</i> hybridization in brain sections from wild-type and Mct8/Oatp1c1 knockout mice at postnatal days 12, 21, and 120. <b><i>Results:</i></b> In total, 59 plasma membrane transporters were selected for screening of TRIAC accumulation (<i>n</i> = 40 based on expression at the human BBB and/or brain-cerebrospinal fluid barrier and having small organic molecules as substrates; <i>n</i> = 19 known thyroid hormone transporters). Screening of the selected transporter panel showed that 18 transporters facilitated significant intracellular accumulation of TRIAC in DPBS/0.1% glucose or DMEM in the absence of BSA. In the presence of BSA, substantial transport was noted for SLCO1B1 and SLC22A8 (in DPBS/0.1% glucose and DMEM) and SLC10A1, SLC22A6, and SLC22A24 (in DMEM). The zebrafish and mouse orthologs of these transporters similarly facilitated intracellular accumulation of TRIAC. Highest Slc22a8 mRNA expression was detected in mouse brain capillary endothelial cells and choroid plexus epithelial cells at early postnatal time points, but was reduced at P120. <b><i>Conclusions:</i></b> Human SLC10A1, SLCO1B1, SLC22A6, SLC22A8, and SLC22A24 as well as their mouse and zebrafish orthologs are efficient TRIAC transporters. These findings contribute to the understanding of TRIAC treatment in patients with MCT8 deficiency and animal models thereof.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"1027-1037"},"PeriodicalIF":5.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2023.0467","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Thyroid hormone transporters are essential for thyroid hormones to enter target cells. Monocarboxylate transporter (MCT) 8 is a key transporter and is expressed at the blood-brain barrier (BBB), in neural cells and many other tissues. Patients with MCT8 deficiency have severe neurodevelopmental delays because of cerebral hypothyroidism and chronic sequelae of peripheral thyrotoxicosis. The T3 analog 3,3',5-triiodothyroacetic acid (TRIAC) rescued neurodevelopmental features in animal models mimicking MCT8 deficiency and improved key metabolic features in patients with MCT8 deficiency. However, the identity of the transporter(s) that facilitate TRIAC transport are unknown. Here, we screened candidate transporters that are expressed at the human BBB and/or brain-cerebrospinal fluid barrier and known thyroid hormone transporters for TRIAC transport. Materials and Methods: Plasma membrane expression was determined by cell surface biotinylation assays. Intracellular accumulation of 1 nM TRIAC was assessed in COS-1 cells expressing candidate transporters in Dulbecco's phosphate-buffered saline (DPBS)/0.1% glucose or Dulbecco's modified Eagle's medium (DMEM) with or without 0.1% bovine serum albumin (BSA). Expression of Slc22a8 was determined by fluorescent in situ hybridization in brain sections from wild-type and Mct8/Oatp1c1 knockout mice at postnatal days 12, 21, and 120. Results: In total, 59 plasma membrane transporters were selected for screening of TRIAC accumulation (n = 40 based on expression at the human BBB and/or brain-cerebrospinal fluid barrier and having small organic molecules as substrates; n = 19 known thyroid hormone transporters). Screening of the selected transporter panel showed that 18 transporters facilitated significant intracellular accumulation of TRIAC in DPBS/0.1% glucose or DMEM in the absence of BSA. In the presence of BSA, substantial transport was noted for SLCO1B1 and SLC22A8 (in DPBS/0.1% glucose and DMEM) and SLC10A1, SLC22A6, and SLC22A24 (in DMEM). The zebrafish and mouse orthologs of these transporters similarly facilitated intracellular accumulation of TRIAC. Highest Slc22a8 mRNA expression was detected in mouse brain capillary endothelial cells and choroid plexus epithelial cells at early postnatal time points, but was reduced at P120. Conclusions: Human SLC10A1, SLCO1B1, SLC22A6, SLC22A8, and SLC22A24 as well as their mouse and zebrafish orthologs are efficient TRIAC transporters. These findings contribute to the understanding of TRIAC treatment in patients with MCT8 deficiency and animal models thereof.

3,3',5-三碘甲状腺乙酸(TRIAC)转运体。
导言 甲状腺激素转运体是甲状腺激素进入靶细胞的关键。单羧酸盐转运体MCT8是一种关键的转运体,在血脑屏障、神经细胞和许多其他组织中都有表达。MCT8缺乏症患者会因大脑甲状腺功能减退和外周甲状腺中毒慢性后遗症而导致严重的神经发育迟缓。T3类似物3,3,5-三碘甲状腺乙酸(TRIAC)能挽救模拟MCT8缺乏症的动物模型的神经发育特征,并改善MCT8缺乏症患者的主要代谢特征。然而,促进 TRIAC 转运的转运体的身份尚不清楚。在此,我们筛选了在人血脑屏障和/或脑-脑脊液屏障表达的候选转运体以及已知的甲状腺激素转运体,以确定其是否能促进 TRIAC 转运。材料与方法 通过细胞表面生物素化试验确定质膜表达。在杜氏磷酸盐缓冲盐水(DPBS)/0.1% 葡萄糖或含或不含 0.1% 牛血清白蛋白(BSA)的杜氏改良老鹰培养基(DMEM)中表达候选转运体的 COS-1 细胞中,评估 1 nM TRIAC 的胞内积累。通过荧光原位杂交(FISH)测定野生型小鼠和Mct8/Oatp1c1基因敲除小鼠在出生后第12、21和120天的脑切片中Slc22a8的表达。结果 筛选出59个质膜转运体用于筛选TRIAC的积累(40个基于在人类血脑屏障和/或脑-脑脊液屏障的表达,并以有机小分子为底物;19个已知的甲状腺激素转运体)。对所选转运体面板的筛选显示,在 DPBS/0.1% 葡萄糖或 DMEM 中,如果没有 BSA,18 个转运体可促进 TRIAC 在细胞内大量积累。在有 BSA 存在的情况下,SLCO1B1 和 SLC22A8(在 DPBS/0.1% 葡萄糖和 DMEM 中)以及 SLC10A1、SLC22A6 和 SLC22A24(在 DMEM 中)均有大量转运。这些转运体的斑马鱼和小鼠同源物同样促进了 TRIAC 的细胞内积累。在小鼠脑毛细血管内皮细胞和脉络丛上皮细胞中,SLC22a8 mRNA的表达量在出生后早期达到最高,但在P120时有所下降。结论 人类 SLC10A1、SLCO1B1、SLC22A6、SLC22A8 和 SLC22A24 以及它们的小鼠和斑马鱼直向同源物是高效的 TRIAC 转运体。这些发现有助于人们了解如何治疗 MCT8 缺乏症患者及其动物模型中的 TRIAC。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信